CASE REPORT

Gastric Outlet Obstruction Due to Gastric Amyloidosis Mimicking Malignancy in a Patient with Ankylosing Spondylitis

Choon Sik Seon, Young Sook Park, Yu Min Jung, Jeong Ho Choi, Byoung Kwan Son, Sang Bong Ahn, Seong Hwan Kim and Yun Ju Jo
Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea

Amyloidosis is a group of disorders characterized by the extracellular accumulation of insoluble, fibrillar proteins in various organs and tissues. It is classified, on the basis of the identity of the precursor protein, as primary, secondary, or familial amyloidosis. Gastrointestinal amyloidosis usually presents as bleeding, ulceration, malabsorption, protein loss, and diarrhea. However, gastric amyloidosis with gastric outlet obstruction mimicking linitis plastica is rare. We report a case of gastrointestinal amyloidosis with gastric outlet obstruction in a patient with ankylosing spondylitis. The patient was indicated for subtotal gastrectomy because of the aggravation of obstructive symptoms, but refused the operation and was transferred to another hospital. Three months later, the patient died of aspiration pneumonia during medical treatment.

Key Words: Gastrointestinal amyloidosis; Spondylitis, ankylosing; Linitis plastica

INTRODUCTION

Secondary (AA) amyloidosis is a systemic disease caused by the deposition of amyloid in various tissues and organs leading to impaired function. It occurs most frequently in patients with poorly controlled chronic inflammatory disease, mainly rheumatoid arthritis, and ankylosing spondylitis. In systemic amyloidosis, the usual presentation is renal involvement, and the gastrointestinal tract is commonly involved. Patients with gastric involvement present with various symptoms such as nausea, vomiting, hematemesis, and epigastric pain. Most studies emphasize the presence of stomach motility disturbances in amyloidosis. However, there have been few case reports of systemic amyloidosis with gastric outlet obstruction. Here, we report a case of systemic AA amyloidosis with gastric outlet obstruction mimicking linitis plastica secondary to ankylosing spondylitis.

CASE REPORT

A 65-year-old woman was referred to us because of abdominal distention, nausea, and vomiting that had been occurring for a month. Her medical history includes a diagnosis of ankylosing spondylitis 1 year ago, and she had been taking celecoxib daily. Physical examination revealed decreased bowel sounds and direct tenderness in the lower abdomen. Complete blood cell count showed a leukocyte number of 7,470/µL, hemoglobin of 8.8 g/dL, and platelet count of 301,000/mm³. Her blood chemistry values were as follows: total protein, 6.1 g/dL; albumin, 3.1 g/dL; total bilirubin, 0.4 mg/dL; aspartate aminotransferase, 26 U/L; alanine aminotransferase, 16 U/L; alkaline phosphatase, 368 U/L; blood urea nitrogen, 16.6 mg/dL; creatinine, 1.4 mg/dL; erythrocyte sedimentation rate, 79 mm/hr; and C-reactive protein, 2.8 mg/dL. Blood coagulation test revealed a prothrombin time/activated partial thromboplastin time of 11.8/29.5 seconds. Abdominal radiography showed a huge gastric shadow with a large amount of food materials in the stomach and diffuse wall thickening of the gastric antrum (Fig. 1A). Endoscopy revealed marked edema of the mucosa, multiple ulcerations, and luminal narrowing and limited distensibility of the gastric antrum (Fig. 1B). Endos-
copy also showed pyloric stenosis with ulceration (Fig. 1C),
but endoscopic mucosal change was not observed in the du-
odenum (Fig. 1D). We performed endoscopic biopsies of the
gastric antrum and the duodenum, which revealed the depo-
sition of eosinophilic amorphous materials in the lamina
propria and the submucosa in the stomach but not in the du-
odenum on hematoxylin and eosin staining (Fig. 2), and the
accumulation of apple-green materials in the lamina propria.

Fig. 1. (A) Computed tomography of the stomach showing a large amount of food stasis with focal submucosal thickening in the gastric an-
trum. (B) Endoscopic finding of the gastric antrum showing marked edema of the mucosa, multiple ulcerations, and luminal narrowing of the
gastric antrum. (C) Endoscopic finding of the pylorus showing pyloric stenosis with ulceration. (D) Endoscopic finding of the duodenal bulb
showing a normal appearance.

Fig. 2. (A) Photomicrograph of the gastric biopsy specimen showing deposition of eosinophilic amorphous materials in the lamina propria
and the submucosa of the gastric antrum, consistent with amyloidosis (H&E stain, ×200). (B) Photomicrograph of the duodenal biopsy
specimen showing deposition of amyloid fibrils in the lamina propria and the submucosa of the duodenum (H&E stain, ×200).
and the submucosa in the stomach on Congo red staining (Fig. 3A, B). Electron microscopy showed amyloid fibrils in the subepithelial layers (Fig. 3C, D). The histological findings were compatible with amyloidosis, and the amyloid was identified as the AA type on immunohistochemical testing with monoclonal antibodies specific to serum amyloid A protein. Colonoscopy with random biopsies showed no colonic involvement by the amyloidosis. Bence-Jones proteins were present in urine, but an M-peak was not found in serum. Moreover, there were no abnormalities on bone marrow biopsy. Her final diagnosis was amyloidosis secondary to ankylosing spondylitis presenting with gastric outlet obstruction. Subtotal gastrectomy was recommended because of the worsening obstruction symptoms; however, she refused surgery and wanted to be transferred to another hospital. Three months later, she died of aspiration pneumonia during medical treatment.

**DISCUSSION**

Amyloidosis is a group of disorders characterized by the accumulation of amyloid in various organs and tissues of the body. It is categorized according to the tissue distribution of the amyloid as systemic or localized amyloidosis, and according to the presence or absence of the predisposing factors as AA or primary (AL) amyloidosis. Serum amyloid A protein is an acute phase reactant that is produced because of chronic infection or inflammation. The most common causes of AA amyloidosis are inflammatory arthritides and spondyloarthropathies. The prevalence of AA amyloidosis in patients with ankylosing spondylitis was estimated to be from 4.4% to 8.6%.

The frequency of clinically apparent gastrointestinal involvement varies with the type of amyloidosis. Gastrointestinal disease is present in as many as 60% of patients with AA amyloidosis. In cases of gastrointestinal tract involvement, gastrointestinal symptoms include gastrointestinal bleeding, chronic intestinal dysmotility, malabsorption, and protein-losing enteropathy. AA amyloidosis presents with diarrhea and malabsorption, whereas AL amyloidosis usually presents with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction. Especially, amyloidosis with gastric involvement presents with gastroparesis, epigastric pain, gastric outlet obstruction, gastric amyloid tumors, peptic ulceration, hematemesis, and melena. Gastric amyloidosis with obstructive symptoms is usually due to submucosal tumors, polyps, or antral narrowing but rarely due to lesions similar to linitis plastica. Endoscopically, AL amyloidosis typically forms a polypoid mass lesion and AA amyloidosis shows a fine granular appearance.
Secondary Amyloidosis Mimicking Malignancy

In our case, the patient presented with gastric outlet obstruction, which is unusual in AA amyloidosis. Moreover, endoscopically, she showed multiple ulcerations on the edematous mucosa of the antrum in the stomach, which showed a poorly demarcated margin suggestive of gastric lymphoma or linitis plastica. Gastric amyloidosis could be misdiagnosed as gastric cancer because of the likeness in endoscopic and radiologic findings. Bedioui et al. reported a case of gastric amyloidosis mimicking linitis plastica. Although they performed various examinations, including gastroscopy with biopsy, barium meal, and endoscopic ultrasonography, they did not find any evidence of amyloidosis. However, they finally diagnosed amyloidosis after a subtotal gastrectomy.

Although most of the gastric amyloidosis cases are not related to gastric cancer, some might be associated with gastric malignancies. In such cases, the confirmative diagnostic method is biopsy. The amyloid displays amorphous, homogenous, translucent, and acidophilic materials under a light microscope on hematoxylin and eosin staining. With Congo red staining, the amyloid could be observed as an apple-green birefringence under polarized light. Under an electron microscope, the amyloid is seen as thin linear fibrils. In our case, we found apple-green birefringence under the light microscope and thread-like fibrils under the electron microscope on Congo red staining. It involved the stomach and the duodenum but there was no colonic involvement. Analysis of monoclonal immunoglobulin in serum and urine has little role in the diagnosis of AA amyloidosis but could help exclude AL amyloidosis.

The treatment of AA amyloidosis is focused on the treatment of the underlying inflammatory disease, whereas the mainstay treatment for AL amyloidosis has been chemotherapy. Recently, several reports have described the benefits of tumor necrosis factor-α (TNF-α) inhibitors in patients with AL amyloidosis secondary to chronic inflammatory disease. These agents have a remarkable ability to suppress inflammatory reactions. Two reports about AA amyloidosis and TNF-α inhibitor therapies showed improvement of proteinuria and renal function in patients with renal amyloidosis secondary to ankylosing spondylitis. However, studies on the treatment of gastrointestinal amyloidosis especially for patients with ankylosing spondylitis are limited. McMahon et al. emphasized the importance of early treatment with a TNF-α inhibitor for gastrointestinal amyloidosis secondary to ankylosing spondylitis because delayed treatment might prevent patients from obtaining the full benefits of the drug.

The prognosis of amyloidosis differs according to type. AL amyloidosis has a poor prognosis with a median survival of <2 years despite treatment with mephalan and steroids. The prognosis of AA amyloidosis differs according to the underlying disease and is correlated with serum amyloid A concentration. A cohort study of patients with systemic AA amyloidosis showed a median survival of 133 months. In that cohort study, mortality, amyloid burden, and renal prognosis were all significantly correlated with the serum amyloid A concentration during follow-up. The risk of death was 17.7 times higher in patients with serum amyloid A concentrations of ≥155 mg/L compared to that in those with concentrations of 4 mg/L. Whole-body 123I-labeled serum amyloid P component scintigraphy for measuring the concentration of serum amyloid A is not commercially used in Korea yet, so we were not able to measure the amyloid burden in our patient.

In this case, the patient presented with nonspecific symptoms such as nausea, vomiting, and abdominal distention, and endoscopy showed segmental luminal narrowing similar to linitis plastica, which is rare in patients with AA amyloidosis. However, with suspicion, we performed Congo red staining and finally concluded a diagnosis of amyloidosis secondary to ankylosing spondylitis. Therefore, in a patient with long-standing ankylosing spondylitis, gastric amyloidosis should be differentiated when the patient presents with gastric outlet obstruction.

Conflicts of Interest
The authors have no financial conflicts of interest.

REFERENCES
1. Husby G. Amyloidosis. Semin Arthritis Rheum 1992;22:67-82.
2. Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007;356:2413-2415.
3. Lee JC, Wilson JA, Gottfried MR. Gastrointestinal manifestations of amyloidosis. South Med J 1994;87:243-247.
4. Menke DM, Kyle RA, Fleming CR, Wolfe JF 3rd, Kurkin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993;68:763-767.
5. Steen LE, Oberg L. Familial amyloidosis with polyneuropathy: roentgenological and gastroscopic appearance of gastrointestinal involvement. Am J Gastroenterol 1983;78:417-420.
6. Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001;356:203-210.
7. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-176.
8. Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama H. Amyloidosis in rheumatoid arthritis: clinical study of 124 histologically proven cases. Ryuamachi 1994;34:939-946.
9. Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc 1994;40:45-50.
10. Setternayagam P, Hawkins P, Gillmore J. Amyloid and the GI tract. Expert Rev Gastroenterol Hepatol 2009;3:615-630.
11. Klingenberg PF. Amyloidosis of gastrointestinal tract simulating gastric carcinoma. Am J Surg 1958;96:713-715.
12. Jensen K, Raynor S, Rose SG, Bailey ST, Schenklen JR. Amyloid tumors of the gastrointestinal tract: a report of two cases and review of the literature. Am J Gastroenterol 1985;80:784-786.
14. Bedioui H, Chebbi F, Ayadi S, et al. Gastric amyloidosis mimicking malignancy. A case report. Ann Chir 2006;131:455-458.
15. Aoyagi K, Koufuji K, Yano S, et al. Early gastric carcinoma associated with amyloidosis: a case report. Kurume Med J 2002;49:153-156.
16. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
17. McMahan ZH, Sailors JL, Toto R, Olsen NJ. Systemic amyloidosis presenting as chronic diarrhea in a patient with ankylosing spondylitis. J Clin Rheumatol 2010;16:22-25.
18. Kobak S, Oksel F, Kabasakal Y, Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007;26:2191-2194.
19. Fernández-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-556.
20. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371.